About: Halofuginone Hydrobromide

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Halofuginone Hydrobromide Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Class, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	Class
rdfs:label	Halofuginone Hydrobromide
rdfs:subClassOf	Angiogenesis Activator Inhibitor
Has_Free_Acid_Or_Base_Form	Halofuginone
Has_Target	Matrix Metalloproteinase 2 Transforming Growth Factor beta Collagen I (Alpha 1) Collagen I (Alpha 2)
Concept_In_Subset	FDA Established Names and Unique Ingredient Identifier Codes Terminology
Semantic_Type	Organic Chemical Pharmacologic Substance
Preferred_Name	Halofuginone Hydrobromide
NSC_Code	713205
UMLS_CUI	C0521922
CAS_Registry	17395-31-2 64924-67-0
Accepted_Therapeutic_Use_For	Scleroderma and Antiprotozoal; Coccidiosis (Vet).
In_Clinical_Trial_For	Topically in Patients with HIV-Related Kaposis Sarcoma and Progressive Advanced Solid Tumors.
FDA_UNII_Code	PTC2969MV1
Contributing_Source	FDA
ALT_DEFINITION	A substance that is being studied for its ability to slow the growth of connective tissue and to prevent the growth of new blood vessels that tumors need to grow. It is a type of quinazolinone alkaloid and a type of antiangiogenesis agent.NCI-GLOSS
PDQ_Open_Trial_Search_ID	38485
PDQ_Closed_Trial_Search_ID	38485
Chemical_Formula	C16H17BrClN3O3.BrH
Legacy_Concept_Name	Halofuginone_Hydrobromide
FULL_SYN	TempostatinBRNCI Halofuginone HydrobromidePTDCP09501 halofuginone hydrobromidePTNCI-GLOSSCDR0000045060 Halofuginone HydrobromidePTNCI HALOFUGINONE HYDROBROMIDEPTFDAPTC2969MV1 Halofuginone IV (intravenous)SYNCI RU 19110CNNCI Halofuginone hydrobromideSYDTPNSC0713205
DEFINITION	The hydrobromide salt of halofuginone, a semisynthetic quinazolinone alkaloid anticoccidial derived from the plant Dichroa febrifuga, with antifibrotic and potential antineoplastic activities. Halofuginone specifically inhibits collagen type I gene expression and matrix metalloproteinase 2 (MMP-2) gene expression, which may result in the suppression of angiogenesis, tumor stromal cell development, and tumor cell growth. These effects appear to be due to halofuginone-mediated inhibition of the collagen type I and MMP-2 promoters. Collagen type I and MMP-2 play important roles in fibro-proliferative diseases.NCI
code	C2656
is Has_Salt_Form of	Halofuginone

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 40 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software